Nephros (NASDAQ:NEPH) Trading Up 0.7%

Shares of Nephros, Inc. (NASDAQ:NEPH) shot up 0.7% on Wednesday . The company traded as high as $2.09 and last traded at $2.08. 1,769 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 17,031 shares. The stock had previously closed at $2.06.

Analysts Set New Price Targets

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $5.00 price target on shares of Nephros in a research report on Wednesday, May 15th.

Nephros Stock Performance

The company has a 50-day simple moving average of $2.17 and a 200 day simple moving average of $2.69. The company has a market capitalization of $21.87 million, a P/E ratio of -14.82 and a beta of 1.19.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.02) EPS for the quarter. The business had revenue of $3.52 million during the quarter. Nephros had a negative return on equity of 17.01% and a negative net margin of 10.23%.

Insiders Place Their Bets

In other Nephros news, CEO Robert R. Jr. Banks purchased 50,000 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were bought at an average cost of $2.24 per share, with a total value of $112,000.00. Following the transaction, the chief executive officer now directly owns 70,000 shares in the company, valued at approximately $156,800. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have acquired a total of 55,000 shares of company stock valued at $123,160 in the last three months. Company insiders own 4.10% of the company’s stock.

Institutional Trading of Nephros

A hedge fund recently bought a new stake in Nephros stock. Mesirow Financial Investment Management Inc. acquired a new position in shares of Nephros, Inc. (NASDAQ:NEPH) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 15,383 shares of the company’s stock, valued at approximately $34,000. Mesirow Financial Investment Management Inc. owned approximately 0.15% of Nephros at the end of the most recent quarter. Institutional investors and hedge funds own 41.10% of the company’s stock.

About Nephros

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.